The estimated Net Worth of Robert S Epstein is at least $6.68 Milion dollars as of 24 May 2023. Robert Epstein owns over 7,600 units of Illumina Inc stock worth over $1,842,990 and over the last 12 years he sold ILMN stock worth over $4,338,084. In addition, he makes $497,617 as Independent Director at Illumina Inc.
Sign up
Robert Epstein ILMN stock SEC Form 4 insiders trading
Robert has made over 30 trades of the Illumina Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 7,600 units of ILMN stock worth $540,284 on 24 May 2023.
The largest trade he's ever made was exercising 10,000 units of Illumina Inc stock on 13 July 2020 worth over $52,800. On average, Robert trades about 781 units every 43 days since 2012. As of 24 May 2023 he still owns at least 14,764 units of Illumina Inc stock.
You can see the complete history of Robert Epstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Epstein biography
Dr. Robert S. (Rob) Epstein, M.D. is an Independent Director of Illumina Inc. since November 29, 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves as a director of AVEO Pharmaceuticals, Inc. a NASDAQ-listed cancer therapeutics company, and Proteus Digital Health, a privately-held healthcare technology company. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association). Dr. Epstein received his medical degree and B.S. in Biomedical Science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland. In selecting Dr. Epstein as a past nominee for election to the Board of Directors, the Board considered, among other things, Dr. Epstein’s in-depth experience and practical knowledge of how molecular diagnostic tests are reimbursed and the issues raised by payors and other evidentiary authorities. As our technology and products are increasingly utilized in clinical settings, Dr. Epstein’s experience will contribute to the Board’s understanding of these markets and the risks and opportunities associated with operating in markets regulated by the U.S. Food and Drug Administration.
What is the salary of Robert Epstein?
As the Independent Director of Illumina Inc, the total compensation of Robert Epstein at Illumina Inc is $497,617. There are 14 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of $3,541,310.
How old is Robert Epstein?
Robert Epstein is 64, he's been the Independent Director of Illumina Inc since 2012. There are 2 older and 20 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
What's Robert Epstein's mailing address?
Robert's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Illumina Inc
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley oraz Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
What does Illumina Inc do?
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
What does Illumina Inc's logo look like?
Complete history of Robert Epstein stock trades at AVEO Pharmaceuticals Inc, Fate Therapeutics Inc, Illumina Inc oraz Veracyte Inc
Illumina Inc executives and stock owners
Illumina Inc executives and other stock owners filed with the SEC include:
-
Mostafa Ronaghi,
Senior Vice President of Entrepreneurial Development -
Mark Van Oene,
Senior Vice President, Chief Commercial Officer -
Jay Flatley,
Executive Chairman of the Board -
Joydeep Goswami,
Senior Vice President - Corporate Development and Strategic Planning -
Charles Dadswell,
Senior Vice President, General Counsel, Secretary -
Francis deSouza,
President, Chief Executive Officer, Director -
Susan Siegel,
Independent Director -
Dr. Alexander Aravanis M.D., Ph.D.,
CTO & Head of Research and Product Devel. -
Aimee Hoyt,
Senior Vice President and Chief People Officer -
Sam A. Samad,
Chief Financial Officer -
Susan H. Tousi,
Chief Commercial Officer -
Sam Samad,
Chief Financial Officer, Senior Vice President -
Caroline Dorsa,
Independent Director -
John Thompson,
Lead Independent Director -
Robert Epstein,
Independent Director -
Gary Guthart,
Independent Director -
Frances Arnold,
Independent Director -
Philip Schiller,
Independent Director -
Jacquie Ross,
Vice President, Investor Relations -
Scott Gottlieb,
Independent Director -
Alex Aravanis,
Chief Technology Officer -
Phillip Febbo,
Senior Vice President, Chief Medical Officer -
Carissa Rollins,
Chief Information Officer -
Sallilyn Schwartz,
VP of Investor Relations -
Kevin Carl Pegels,
Chief of Global Operations -
Francis A. deSouza,
CEO & Director -
Charles E. Dadswell,
Sr. VP, Gen. Counsel & Sec. -
Juliet Cunningham,
VP of Investor Relations -
Steve Phillpott,
Sr. VP & Chief Information Officer -
Jose A. Torres Jr.,
Chief Accounting Officer & VP -
Robert P. Ragusa,
Chief Operations Officer -
Stephanie Campos,
Pres -
Kathryne Gambrell Reeves,
SVP, Chief Marketing Officer -
Daniel Bradbury,
Director -
A Blaine Bowman,
Director -
Omead Ostadan,
SVP Mktg, Prod & Strat Plan -
Karin Eastham,
Director -
Patricia Leckman,
SVP, Chief People Officer -
Malcolm Garret Hampton,
SVP Clinical Genomics Group -
Karen K Mcginnis,
VP, Chief Accounting Officer -
Jacob Thaysen,
Chief Executive Officer -
Robert P Ragusa,
SVP, Global Quality & Ops -
Susan H Tousi,
SVP, Chief Commercial Officer -
David R Walt,
Director -
William H Rastetter,
Director -
Nicholas Naclerio,
Sr VP, Corporate & Venture Dev -
Tristan Orpin,
VP Worldwide Sales -
Richard Klausner,
Sr VP, Chief Medical Officer -
Roy A Whitfield,
Director -
Jeff Huber,
Director -
Marc Stapley,
Sr VP & CFO -
Gerald Moeller,
Director -
Paul L Bianchi,
Sr VP, Human Resources -
Michel Bouchard,
Chief Accounting Officer -
Mark L Lewis,
Sr VP & GM Molecular Biology -
Gregory Heath,
Sr. VP and GM, Diagnostics -
Matthew L. Posard,
Sr VP & GM, Consumer Genomics -
Christian O Henry,
CFO, VP Finance -
Paul C Grint,
Director -
Christian Cabou,
Sr. VP and General Counsel -
Jack Goldstein,
Director -
Joel Mc Comb,
Sr. VP and GM, Life Sciences -
Stephen P Macmillan,
Director -
Alan Kersey,
V.P. & Site Manager -
John R Stuelpnagel,
VP Business Development -
John West,
Sr VP & GM DNA Sequencing -
David C Douglas,
Vice President Manufacturing -
Scott D Kahn,
Chief Information Officer -
Paulette D Cabral,
Vice President Human Resources -
Timothy M Kish,
VP Finance & CFO -
Arnold R Oliphant,
VP Scientific Operations -
R Scott Greer,
Director -
Arthur Holden,
Sr. VP Corp and Market Dev -
David L Barker,
Chief Scientific Officer -
Ventures Iii Lp Cw,
10% owner -
Clinton Bybee,
10% owner -
Keith Crandell,
10% owner -
Kirk Malloy,
V.P. of Customer Solutions -
George Poste,
Director -
Robert Nelsen,
Director -
Noemi C Espinosa,
VP Intellectual Property -
Robert C Kain,
Vice President Engineering -
Steven Lazarus,
10% owner -
Venture Fund Iii L P Arch,
10% owner -
Venture Partners Llc Arch,
10% owner -
Christensen Jakob Wedel,
SVP, Strategy/Corp Development -
Ankur Dhingra,
SVP, Chief Financial Officer -
Anna Richo,
Director -
Jose Torres,
VP, Chief Accounting Officer -
Kevin Carl Pegels,
Chief of Global Operations -
Scott B. Ullem,
Director -
Carissa Rollins,
SVP, Chief Information Officer -
John Edward Frank,
Chief Public Affairs Officer -
Steven Barnard,
SVP, Chief Technology Officer -
Scott D Ericksen,
VP, Chief Accounting Officer -
Everett Cunningham,
SVP, Chief Commercial Officer